Ganirelix Acetate Market Segmentation:
- By Dosage Form
- Injection
- Powder
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Fertility Clinics
- Others
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Frequently Asked Questions
The Ganirelix Acetate Market is estimated to be USD 423 million in 2024.
Increasing infertility rates, growth of IVF procedures, new product launches, government funding for ART, andmedical tourism for fertility treatments.
High treatment costs, low awareness levels, side effects, and stringent regulatory policies for drug approvals.
The injectable dosage form segment dominates the Ganirelix Acetate Market with over 90% share.
Merck & Co., Ferring Pharmaceuticals, Sun Pharmaceuticals, Cook Medical, Vetter Pharma-Fertigung, and Monash IVF.
The global market is expected to reach USD 615.3 million by 2031 growing at a CAGR of 5.5% during 2024-2031.
Rising infertility rates, increase in IVF procedures, growth in fertility tourism, favorable reimbursement policies, product launches and mergers and acquisitions.